Cervical squamous cell carcinoma is one of the predominant histological subtypes of cervical cancer, with significant morbidity and mortality globally. Its management increasingly relies on the ...

Cervical cancer treatment trajectories in a sample of cervical cancer patients in the Democratic Republic of the Congo: A retrospective descriptive study. This is an ASCO Meeting Abstract from the ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) said it has aligned with the U.S. Food and Drug Administration on the regulatory pathway for CRB-701, its Nectin-4–targeting antibody-drug conjugate ...

FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential ...

The FDA has agreed on the design of two randomized phase 3 trials evaluating CRB-701, a next-generation Nectin-4-targeted ...

Effect of adverse outcomes—septicemias, healthcare complications, coagulopathies, and cardiac arrhythmias—on the burden of illness and related disparities among hospitalized cervical cancer patients ...

Maxillary squamous cell carcinoma (MSCC) represents a relatively uncommon subset of head and neck cancers; however, its aggressive nature and propensity for early cervical lymph node involvement ...

For patients with pretreated recurrent or metastatic cervical cancer, treatment with camrelizumab plus famitinib improved antitumor activity with a "manageable safety profile," researchers reported.

Researchers from Xinjiang Medical University used single-cell RNA sequencing to identify PI3+S100A7+ keratinocytes in early-stage HPV-positive cervical cancer. These cells interact closely with immune ...

Booking Health, a global medical travel provider, announced today the release of its 2026 report on advanced head and neck ...

Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical ...